Lipid-lowering therapy after myocardial infarction: strike early, strong, and equally in women and men

Gal Tsaban^{1

2}, Barbara Vitola^{3

4}

Affiliations

¹ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
² Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel.
³ Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia.
⁴ Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia.

Editorial

Gal Tsaban et al. Eur J Prev Cardiol. 2024.

. 2024 Nov 11;31(15):1861-1862.

doi: 10.1093/eurjpc/zwae319.

Gal Tsaban^{1

2}, Barbara Vitola^{3

4}

¹ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
² Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel.
³ Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia.
⁴ Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

Prognostic impact of high-intensity lipid-lowering therapy under-prescription after acute myocardial infarction in women.
Weizman O, Hauguel-Moreau M, Tea V, Albert F, Barragan P, Georges JL, Delarche N, Kerneis M, Bataille V, Drouet E, Puymirat E, Ferrières J, Schiele F, Simon T, Danchin N; FAST-MI Investigators. Weizman O, et al. Eur J Prev Cardiol. 2024 Nov 11;31(15):1850-1860. doi: 10.1093/eurjpc/zwae255. Eur J Prev Cardiol. 2024. PMID: 39192488